 For people with relapsed AML , the only proven potentially curative therapy is a hematopoietic stem cell transplant , if one has not already been performed . In 2000 , the monoclonal antibody @-@ linked cytotoxic agent gemtuzumab ozogamicin ( Mylotarg ) was approved in the United States for people aged more than 60 years with relapsed AML who are not candidates for high @-@ dose chemotherapy . This drug was voluntarily withdrawn from the market by its manufacturer , Pfizer in 2010 . 
 For people with relapsed AML , the only proven potentially curative therapy <a href='drop_aux' title='1'><mark>is</mark></a>a hematopoietic stem cell transplant , if one <a href='been_done' title='2'><mark>has</mark></a> not already been performed . In 2000 , the monoclonal antibody @-@ linked cytotoxic agent gemtuzumab ozogamicin ( Mylotarg ) was approved in the United States for people aged more than 60 years with relapsed AML <a href='null_relcl' title='3'><mark>who</mark></a><a href='negative_concord' title='4'><mark>are</mark></a> <a href='negative_concord' title='5'><mark>not</mark></a><a href='negative_concord' title='6'><mark>candidates</mark></a> for high @-@ dose chemotherapy . This drug was voluntarily withdrawn from the market by its manufacturer , Pfizer in 2010 . 
Fir people wit relapsed AML , the only proven potentially curative therapy a hematopoietic stem cell transplant , if one done not already been performed . In 2000 , da monoclonal antibody @-@ linked cytotoxic agent gemtuzumab ozogamicin ( Mylotarg ) was approved in tdaUnited States for people aged more den 60 yrs ww/relapsed AML ain't no candidates for high @-@ dose chemotherapy . dis drug was voluntarily withdrawn from thdaarket by its manufacturer , Pfizer in 2010 .